Top

Published in:

01-11-2009 | Original Article

Association of MicroRNA-223 Expression with Hepatic Ischemia/Reperfusion Injury in Mice

Authors: Chao-Hui Yu, Cheng-Fu Xu, You-Ming Li

Published in: Digestive Diseases and Sciences | Issue 11/2009

Abstract

MicroRNAs are a group of small non-coding RNAs with modulator activity of gene expression. Recent studies have uncovered a profound role of microRNAs in liver diseases. This study aimed to investigate a potential relationship between microRNA-223 (miR-223) expression and hepatic ischemia/reperfusion injury in mice. Quantitative RT-PCR analysis showed that miR-223 expression levels were greatly up-regulated in the livers after 75 min ischemia followed by 120 min reperfusion when compared to sham controls (2.59 ± 0.23 vs. 0.83 ± 0.15; P < 0.01). Correlation analysis also revealed that hepatic miR-223 expression level was significantly positively correlated with serum markers of ischemic injury. By prediction assay of miRNA targets mRNA, acyl-CoA synthetase long-chain family member 3, ephrin A1, and ras homolog gene family member B were predicted to be downstream targets of miR-223. Thus, we conclude that hepatic ischemia/reperfusion injury might be another form of liver disease that is associated with alteration in miR-223 expression.

Selzner N, Rudiger H, Graf R, Clavien PA. Protective strategies against ischemic injury of the liver. Gastroenterology. 2003;125:917–936. doi:10.1016/S0016-5085(03)01048-5.CrossRefPubMed

Serracino-Inglott F, Habib NA, Mathie RT. Hepatic ischemia-reperfusion injury. Am J Surg. 2001;181:160–166. doi:10.1016/S0002-9610(00)00573-0.CrossRefPubMed

Xu C, Yu C, Li Y. Current studies on therapeutic approaches for ischemia/reperfusion injury in steatotic livers. Hepatol Res. 2008;38:851–859. doi:10.1111/j.1872-034X.2008.00354.x.CrossRefPubMed

Huguet C, Gavelli A, Bona S. Hepatic resection with ischemia of the liver exceeding one hour. J Am Coll Surg. 1994;178:454–458.PubMed

Fondevila C, Busuttil RW, Kupiec-Weglinski JW. Hepatic ischemia/reperfusion injury—a fresh look. Exp Mol Pathol. 2003;74:86–93. doi:10.1016/S0014-4800(03)00008-X.CrossRefPubMed

Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl. 2003;9:651–663. doi:10.1053/jlts.2003.50105.CrossRefPubMed

Chan EY, Larson AM, Gernsheimer TB, et al. Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients. Liver Transpl. 2007;13:516–522. doi:10.1002/lt.21082.CrossRefPubMed

Verran D, Kusyk T, Painter D, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl. 2003;9:500–505. doi:10.1053/jlts.2003.50099.CrossRefPubMed

Banga NR, Homer-Vanniasinkam S, Graham A, Al-Mukhtar A, White SA, Prasad KR. Ischaemic preconditioning in transplantation and major resection of the liver. Br J Surg. 2005;92:528–538. doi:10.1002/bjs.5004.CrossRefPubMed

10.

Defamie V, Cursio R, Le Brigand K, et al. Gene expression profiling of human liver transplants identifies an early transcriptional signature associated with initial poor graft function. Am J Transpl. 2008;8:1221–1236. doi:10.1111/j.1600-6143.2008.02249.x.CrossRef

11.

Borozan I, Chen L, Sun J, et al. Gene expression profiling of acute liver stress during living donor liver transplantation. Am J Transpl. 2006;6:806–824. doi:10.1111/j.1600-6143.2006.01254.x.CrossRef

12.

Navarro-Sabate A, Peralta C, Calvo MN, et al. Mediators of rat ischemic hepatic preconditioning after cold preservation identified by microarray analysis. Liver Transpl. 2006;12:1615–1625. doi:10.1002/lt.20863.CrossRefPubMed

13.

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. doi:10.1016/S0092-8674(04)00045-5.CrossRefPubMed

14.

Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008;47:897–907. doi:10.1002/hep.22160.CrossRefPubMed

15.

Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25:2537–2545. doi:10.1038/sj.onc.1209283.CrossRefPubMed

16.

Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology. 2007;133:1166–1174. doi:10.1053/j.gastro.2007.08.002.CrossRefPubMed

17.

Moffat ID, Boutros PC, Celius T, Linden J, Pohjanvirta R, Okey AB. MicroRNAs in adult rodent liver are refractory to dioxin treatment. Toxicol Sci. 2007;99:470–487. doi:10.1093/toxsci/kfm189.CrossRefPubMed

18.

Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol. 2008;48:648–656. doi:10.1016/j.jhep.2008.01.019.CrossRefPubMed

19.

Fukao T, Fukuda Y, Kiga K, et al. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell. 2007;129:617–631. doi:10.1016/j.cell.2007.02.048.CrossRefPubMed

20.

Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008;451:1125–1129. doi:10.1038/nature06607.CrossRefPubMed

21.

Wong QW, Lung RW, Law PT, et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 2008;135:257–269. doi:10.1053/j.gastro.2008.04.003.CrossRefPubMed

22.

Xu C, Zhang X, Yu C, Lu G, Chen S, Xu L, Ding W, Shi Q, Li Y. Proteomic analysis of hepatic ischemia/reperfusion injury and ischemic preconditioning in mice revealed the protective role of ATP5β. Proteomics. 2008. (in press). doi:10.1002/pmic.200800393.

23.

Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115:787–798. doi:10.1016/S0092-8674(03)01018-3.CrossRefPubMed

24.

John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol. 2004;2:e363. doi:10.1371/journal.pbio.0020363.CrossRefPubMed

25.

Vascotto C, Cesaratto L, D’Ambrosio C, et al. Proteomic analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation. Proteomics. 2006;6:3455–3465. doi:10.1002/pmic.200500770.CrossRefPubMed

26.

Carthew RW. Gene regulation by microRNAs. Curr Opin Genet Dev. 2006;16:203–208. doi:10.1016/j.gde.2006.02.012.CrossRefPubMed

27.

Fukushima T, Hamada Y, Yamada H, Horii I. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride—regulating role of micro-RNA for RNA expression. J Toxicol Sci. 2007;32:401–409. doi:10.2131/jts.32.401.CrossRefPubMed

28.

Fujimoto Y, Itabe H, Kinoshita T, et al. Involvement of ACSL in local synthesis of neutral lipids in cytoplasmic lipid droplets in human hepatocyte HuH7. J Lipid Res. 2007;48:1280–1292. doi:10.1194/jlr.M700050-JLR200.CrossRefPubMed

29.

Yamashita T, Ohneda K, Nagano M, et al. Hypoxia-inducible transcription factor-2alpha in endothelial cells regulates tumor neovascularization through activation of ephrin A1. J Biol Chem. 2008;283:18926–18936. doi:10.1074/jbc.M709133200.CrossRefPubMed

30.

Kojima I, Tanaka T, Inagi R, et al. Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol. 2007;18:1218–1226. doi:10.1681/ASN.2006060639.CrossRefPubMed

Title: Association of MicroRNA-223 Expression with Hepatic Ischemia/Reperfusion Injury in Mice
Authors: Chao-Hui Yu
Cheng-Fu Xu
You-Ming Li
Publication date: 01-11-2009
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 11/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0629-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2009

EUS-Guided Celiac Plexus Neurolysis for Pain due to Chronic Pancreatitis or Pancreatic Cancer Pain: A Meta-Analysis and Systematic Review

Comparison of Scoring Systems for the Prediction of Outcomes in Patients with Nonvariceal Upper Gastrointestinal Bleeding: A Prospective Study

Endoscopic Hemostasis in Nonvariceal Upper Gastrointestinal Bleeding: Comparison of Physician Practice in the East and the West

Outcome of Colonoscopy in Elderly African-American Patients

Meta-Analysis of Randomized and Controlled Treatment Trials for Achalasia

Serum Alpha-Fetoprotein Levels During and After Interferon Therapy and the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials